Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.
Schoenfeld DA, Moutafi M, Martinez S, Djureinovic D, Merkin RD, Adeniran A, Braun DA, Signoretti S, Choueiri TK, Parisi F, Hurwitz M, Rimm DL, Wei W, Jilaveanu L, Kluger HM. Schoenfeld DA, et al. Among authors: djureinovic d. J Immunother Cancer. 2023 Aug;11(8):e007240. doi: 10.1136/jitc-2023-007240. J Immunother Cancer. 2023. PMID: 37586773 Free PMC article.
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.
Djureinovic D, Weiss SA, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto AL, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech SM, Bosenberg M, Jilaveanu LB, Kluger HM. Djureinovic D, et al. Mol Cancer. 2023 Nov 14;22(1):182. doi: 10.1186/s12943-023-01884-x. Mol Cancer. 2023. PMID: 37964379 Free PMC article.
Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.
Su DG, Schoenfeld DA, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm DL, Khan SA, Halaban R, Kluger HM, Olino K, Galan A, Clune J. Su DG, et al. Among authors: djureinovic d. J Immunother Cancer. 2024 Mar 21;12(3):e008646. doi: 10.1136/jitc-2023-008646. J Immunother Cancer. 2024. PMID: 38519058 Free PMC article.
Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer.
Backman M, La Fleur L, Kurppa P, Djureinovic D, Elfving H, Brunnström H, Mattsson JSM, Lindberg A, Pontén V, Eltahir M, Mangsbo S, Gulyas M, Isaksson J, Jirström K, Kärre K, Leandersson K, Mezheyeuski A, Pontén F, Strell C, Lindskog C, Botling J, Micke P. Backman M, et al. Among authors: djureinovic d. J Pathol. 2021 Nov;255(3):243-256. doi: 10.1002/path.5772. Epub 2021 Aug 26. J Pathol. 2021. PMID: 34339045
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. Weiss SA, et al. Among authors: djureinovic d. Clin Cancer Res. 2021 Sep 1;27(17):4757-4767. doi: 10.1158/1078-0432.CCR-21-0903. Epub 2021 Jun 17. Clin Cancer Res. 2021. PMID: 34140403 Free PMC article. Clinical Trial.
Agonistic CD40 Antibodies in Cancer Treatment.
Djureinovic D, Wang M, Kluger HM. Djureinovic D, et al. Cancers (Basel). 2021 Mar 15;13(6):1302. doi: 10.3390/cancers13061302. Cancers (Basel). 2021. PMID: 33804039 Free PMC article. Review.
32 results